Literature DB >> 33691136

Global analysis of shared T cell specificities in human non-small cell lung cancer enables HLA inference and antigen discovery.

Shin-Heng Chiou1, Diane Tseng2, Alexandre Reuben3, Vamsee Mallajosyula1, Irene S Molina1, Stephanie Conley4, Julie Wilhelmy5, Alana M McSween1, Xinbo Yang6, Daisuke Nishimiya6, Rahul Sinha4, Barzin Y Nabet7, Chunlin Wang1, Joseph B Shrager8, Mark F Berry9, Leah Backhus8, Natalie S Lui8, Heather A Wakelee10, Joel W Neal10, Sukhmani K Padda2, Gerald J Berry11, Alberto Delaidelli12, Poul H Sorensen12, Elena Sotillo13, Patrick Tran13, Jalen A Benson9, Rebecca Richards14, Louai Labanieh15, Dorota D Klysz13, David M Louis1, Steven A Feldman13, Maximilian Diehn16, Irving L Weissman4, Jianjun Zhang17, Ignacio I Wistuba18, P Andrew Futreal19, John V Heymach3, K Christopher Garcia20, Crystal L Mackall21, Mark M Davis22.   

Abstract

To identify disease-relevant T cell receptors (TCRs) with shared antigen specificity, we analyzed 778,938 TCRβ chain sequences from 178 non-small cell lung cancer patients using the GLIPH2 (grouping of lymphocyte interactions with paratope hotspots 2) algorithm. We identified over 66,000 shared specificity groups, of which 435 were clonally expanded and enriched in tumors compared to adjacent lung. The antigenic epitopes of one such tumor-enriched specificity group were identified using a yeast peptide-HLA A∗02:01 display library. These included a peptide from the epithelial protein TMEM161A, which is overexpressed in tumors and cross-reactive epitopes from Epstein-Barr virus and E. coli. Our findings suggest that this cross-reactivity may underlie the presence of virus-specific T cells in tumor infiltrates and that pathogen cross-reactivity may be a feature of multiple cancers. The approach and analytical pipelines generated in this work, as well as the specificity groups defined here, present a resource for understanding the T cell response in cancer.
Copyright © 2021. Published by Elsevier Inc.

Entities:  

Keywords:  EBV; EntS; GLIPH2; LMP2A; NSCLC; T cell receptor repertoire; T cell specificity; TCR; TMEM161A; cancer; cross-reactivity; tumor-infiltrating lymphocyte

Year:  2021        PMID: 33691136     DOI: 10.1016/j.immuni.2021.02.014

Source DB:  PubMed          Journal:  Immunity        ISSN: 1074-7613            Impact factor:   31.745


  17 in total

1.  TCR meta-clonotypes for biomarker discovery with tcrdist3 enabled identification of public, HLA-restricted clusters of SARS-CoV-2 TCRs.

Authors:  Koshlan Mayer-Blackwell; Stefan Schattgen; Liel Cohen-Lavi; Jeremy C Crawford; Aisha Souquette; Jessica A Gaevert; Tomer Hertz; Paul G Thomas; Philip Bradley; Andrew Fiore-Gartland
Journal:  Elife       Date:  2021-11-30       Impact factor: 8.140

2.  Single B Cell Gene Co-Expression Networks Implicated in Prognosis, Proliferation, and Therapeutic Responses in Non-Small Cell Lung Cancer Bulk Tumors.

Authors:  Qing Ye; Nancy Lan Guo
Journal:  Cancers (Basel)       Date:  2022-06-25       Impact factor: 6.575

Review 3.  Bystander T cells in cancer immunology and therapy.

Authors:  Stefanie L Meier; Ansuman T Satpathy; Daniel K Wells
Journal:  Nat Cancer       Date:  2022-02-28

4.  Functional virus-specific memory T cells survey glioblastoma.

Authors:  Jianfang Ning; Noah V Gavil; Shaoping Wu; Sathi Wijeyesinghe; Eyob Weyu; Jun Ma; Ming Li; Florina-Nicoleta Grigore; Sanjay Dhawan; Alexander G J Skorput; Shawn C Musial; Clark C Chen; David Masopust; Pamela C Rosato
Journal:  Cancer Immunol Immunother       Date:  2022-01-10       Impact factor: 6.630

5.  IgE type multiple myeloma exhibits hypermutated phenotype and tumor reactive T cells.

Authors:  Niklas Kehl; Michael Kilian; Julius Michel; Tim R Wagner; Sebastian Uhrig; Alexander Brobeil; Lilli-Sophie Sester; Sven Blobner; Simon Steiger; Michael Hundemer; Niels Weinhold; Karsten Rippe; Stefan Fröhling; Stefan B Eichmüller; Lukas Bunse; Carsten Müller-Tidow; Hartmut Goldschmidt; Michael Platten; Marc-Steffen Raab; Mirco J Friedrich
Journal:  J Immunother Cancer       Date:  2022-10       Impact factor: 12.469

6.  Human Coronary Plaque T Cells Are Clonal and Cross-React to Virus and Self.

Authors:  Roshni Roy Chowdhury; Jessica D'Addabbo; Xianxi Huang; Stefan Veizades; Koki Sasagawa; David M Louis; Paul Cheng; Jan Sokol; Annie Jensen; Alexandria Tso; Vishnu Shankar; Ben Shogo Wendel; Isaac Bakerman; Grace Liang; Tiffany Koyano; Robyn Fong; Allison N Nau; Herra Ahmad; Jayakrishnan Gopakumar; Robert Wirka; Andrew S Lee; Jack Boyd; Y Joseph Woo; Thomas Quertermous; Gunsagar Singh Gulati; Siddhartha Jaiswal; Yueh-Hsiu Chien; Charles Kwok Fai Chan; Mark M Davis; Patricia K Nguyen
Journal:  Circ Res       Date:  2022-04-18       Impact factor: 23.213

7.  Biological controls for standardization and interpretation of adaptive immune receptor repertoire profiling.

Authors:  Johannes Trück; Anne Eugster; Pierre Barennes; Magnolia Bostick; Encarnita Mariotti-Ferrandiz; Christopher M Tipton; Eline T Luning Prak; Davide Bagnara; Cinque Soto; Jacob S Sherkow; Aimee S Payne; Marie-Paule Lefranc; Andrew Farmer
Journal:  Elife       Date:  2021-05-26       Impact factor: 8.140

Review 8.  The role of the tumor microbe microenvironment in the tumor immune microenvironment: bystander, activator, or inhibitor?

Authors:  Jiayao Ma; Lingjuan Huang; Die Hu; Shan Zeng; Ying Han; Hong Shen
Journal:  J Exp Clin Cancer Res       Date:  2021-10-16

9.  Neoadjuvant PD-1 blockade induces T cell and cDC1 activation but fails to overcome the immunosuppressive tumor associated macrophages in recurrent glioblastoma.

Authors:  Alexander H Lee; Lu Sun; Aaron Y Mochizuki; Jeremy G Reynoso; Joey Orpilla; Frances Chow; Jenny C Kienzler; Richard G Everson; David A Nathanson; Steven J Bensinger; Linda M Liau; Timothy Cloughesy; Willy Hugo; Robert M Prins
Journal:  Nat Commun       Date:  2021-11-26       Impact factor: 14.919

Review 10.  Specificity of Adaptive Immune Responses in Central Nervous System Health, Aging and Diseases.

Authors:  Chiara Rickenbach; Christoph Gericke
Journal:  Front Neurosci       Date:  2022-01-20       Impact factor: 4.677

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.